Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 3/2018

01-06-2018 | Case Report

Two-step progression of varenicline-induced autoimmune hepatitis

Authors: Mitsuru Sakakibara, Kazuyoshi Ohkawa, Takatoshi Nawa, Yutaro Abe, Akira Kusakabe, Toshihiro Imai, Kazuhiro Katayama

Published in: Clinical Journal of Gastroenterology | Issue 3/2018

Login to get access

Abstract

We describe a rare case of drug-induced hepatitis due to the smoking cessation agent varenicline in a 46-year-old Asian woman. The liver injury progressed in two steps. First, the liver injury started in the absence of viral/autoimmune responses, and withdrawal of varenicline lowered the increase in the levels of liver enzymes immediately. Such findings suggested varenicline-induced liver injury. Second, hepatitis recurred in association with conversion of antinuclear antibody from negative to positive about 8 weeks after the initial episode. Histology upon recurrence of liver injury revealed interface hepatitis with lymphocytic and lymphoplasmacytic portal inflammatory infiltrates extending into lobules. Such findings suggested autoimmune hepatitis. Corticosteroid treatment was effective for recurrent hepatitis. The clinical course suggests that varenicline caused drug-induced liver injury and subsequent autoimmune hepatitis. Some autoimmune changes were probably involved in the mechanism of varenicline-induced liver injury.
Literature
1.
go back to reference Franck AJ, Sliter LR. Acute hepatic injury associated with varenicline in a patient with underlying liver disease. Ann Pharmacother. 2009;43:1539–43.CrossRefPubMed Franck AJ, Sliter LR. Acute hepatic injury associated with varenicline in a patient with underlying liver disease. Ann Pharmacother. 2009;43:1539–43.CrossRefPubMed
3.
go back to reference Mogensen H, Björnsson ES. Varenicline-induced acute liver injury with jaundice. Hepatology. 2015;61:2110–1.CrossRefPubMed Mogensen H, Björnsson ES. Varenicline-induced acute liver injury with jaundice. Hepatology. 2015;61:2110–1.CrossRefPubMed
4.
go back to reference Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52:730–42.CrossRefPubMedPubMedCentral Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52:730–42.CrossRefPubMedPubMedCentral
5.
go back to reference Stine JG, Northup PG. Autoimmune-like drug-induced liver injury: a review and update for the clinician. Exp Opin Drug Metab Toxicol. 2016;12:1–11.CrossRef Stine JG, Northup PG. Autoimmune-like drug-induced liver injury: a review and update for the clinician. Exp Opin Drug Metab Toxicol. 2016;12:1–11.CrossRef
6.
go back to reference Watanabe M, Shibuya A. Validity study of a new diagnostic scale for drug-induced liver injury in Japan-comparison with two previous scales. Hepatol Res. 2004;30:148–54.CrossRefPubMed Watanabe M, Shibuya A. Validity study of a new diagnostic scale for drug-induced liver injury in Japan-comparison with two previous scales. Hepatol Res. 2004;30:148–54.CrossRefPubMed
7.
go back to reference Lohse AW, Hennes E. Diagnostic criteria for autoimmune hepatitis. Hepatol Res. 2007;37(Suppl 3):S509.CrossRefPubMed Lohse AW, Hennes E. Diagnostic criteria for autoimmune hepatitis. Hepatol Res. 2007;37(Suppl 3):S509.CrossRefPubMed
8.
go back to reference Murata Y, Ogawa Y, Saibara T, et al. Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis. Oncol Rep. 2003;10:97–100.PubMed Murata Y, Ogawa Y, Saibara T, et al. Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis. Oncol Rep. 2003;10:97–100.PubMed
9.
go back to reference Ahbeddou N, Belbaraka R, Fetohi M, et al. Tamoxifen-induced hepatotoxicity. Indian J Cancer. 2011;48:385.CrossRefPubMed Ahbeddou N, Belbaraka R, Fetohi M, et al. Tamoxifen-induced hepatotoxicity. Indian J Cancer. 2011;48:385.CrossRefPubMed
10.
go back to reference Takikawa H, Takamori Y, Kumagi T, et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. Hepatol Res. 2003;27:192–5.CrossRefPubMed Takikawa H, Takamori Y, Kumagi T, et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. Hepatol Res. 2003;27:192–5.CrossRefPubMed
11.
go back to reference Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–38.CrossRefPubMed Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–38.CrossRefPubMed
12.
go back to reference Weiler-Normann C, Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol. 2011;55:747–9.CrossRefPubMed Weiler-Normann C, Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol. 2011;55:747–9.CrossRefPubMed
13.
go back to reference Iwamura S, Kojima Y, Ohka R, et al. Nidome no kanseiken de syouyou chuusintai eshi wo mitome, yakuzai kiinsei jikomenekisei kanen to shindan sita ichirei (A case of drug-induced autoimmune hepatitis demonstrated initial findings of centrilobular necrosis at the second liver biopsy). Kouchi Sekijuuji byouin Igaku Zasshi (Med J Kouchi Redcross Hospital) [published in Japanese]. 2016;21:39–44. Iwamura S, Kojima Y, Ohka R, et al. Nidome no kanseiken de syouyou chuusintai eshi wo mitome, yakuzai kiinsei jikomenekisei kanen to shindan sita ichirei (A case of drug-induced autoimmune hepatitis demonstrated initial findings of centrilobular necrosis at the second liver biopsy). Kouchi Sekijuuji byouin Igaku Zasshi (Med J Kouchi Redcross Hospital) [published in Japanese]. 2016;21:39–44.
14.
go back to reference Bebo BF, Dehghani B, Foster S, et al. Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis. Glia. 2009;57:777–90.CrossRefPubMedPubMedCentral Bebo BF, Dehghani B, Foster S, et al. Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis. Glia. 2009;57:777–90.CrossRefPubMedPubMedCentral
15.
go back to reference Behfarjam F, Sanati MH, Nasseri Moghaddam S, et al. Role of Th1/Th2 cells and related cytokines in autoimmune hepatitis. Turk J Gastroenterol. 2017;28:110–4.CrossRefPubMed Behfarjam F, Sanati MH, Nasseri Moghaddam S, et al. Role of Th1/Th2 cells and related cytokines in autoimmune hepatitis. Turk J Gastroenterol. 2017;28:110–4.CrossRefPubMed
Metadata
Title
Two-step progression of varenicline-induced autoimmune hepatitis
Authors
Mitsuru Sakakibara
Kazuyoshi Ohkawa
Takatoshi Nawa
Yutaro Abe
Akira Kusakabe
Toshihiro Imai
Kazuhiro Katayama
Publication date
01-06-2018
Publisher
Springer Japan
Published in
Clinical Journal of Gastroenterology / Issue 3/2018
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-018-0824-x

Other articles of this Issue 3/2018

Clinical Journal of Gastroenterology 3/2018 Go to the issue